Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 3/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | PPIA | P62937 | 2/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | DDO | Q99489 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9140835 | 0.78 | CES2 (0.50) | CES2MEN1KMT2A | |
| SCHEMBL23707669 | 0.78 | CES2 (0.50) | CES2MEN1KMT2A | |
| SCHEMBL5426438 | 0.77 | PBRM1 (0.39) | HTR2BHTR2CCES1HTR7PBRM1 | |
| SCHEMBL22276494 | 0.77 | CA1 (0.38) | CA1CA2CA7CA9HTR2B | |
| SCHEMBL25309741 | 0.77 | HTR2C (0.36) | CA1CA2CA7CA9HTR2B | |
| SCHEMBL23963013 | 0.77 | ADORA2A (0.37) | CES2MEN1KMT2APDK2 | |
| SCHEMBL18826578 | 0.77 | CA1 (0.38) | CA1CA2CA7CA9HTR2B | |
| SCHEMBL3554511 | 0.77 | HTR2C (0.41) | HTR2BHTR2CPDK2 | |
| SCHEMBL7825909 | 0.76 | ALDH1A1 (0.44) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL3374566 | 0.74 | ERN1 (0.37) | CA1CA2CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3445357-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| WO-2009145719-A1 | ISOINDOLINE DERIVATIVES COMPRISING A CYANO GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009145721-A1 | ISOINDOLINE DERIVATIVES COMPRISING PHENYL GROUPS AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009145718-A1 | ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-4697005-A | 1-fluoro, 4-fluoro, and 1,4-difluoro anthracycline anticancer antibiotics | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1987-09-29 | — | — | US | disclosed |
| US-4663445-A | ANTITUMOR AGENTS | THE OHIO STATE RESEARCH FOUNDATION (US) | 1987-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CA1 3129/4885CA2 4738/4885CA7 3940/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | CA1 3129/4885CA2 4738/4885CA7 3940/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | CA1 3129/4885CA2 4738/4885CA7 3940/4885 |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | CA1 1220/4885CA2 1737/4885CA7 1775/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CA1 3129/4885CA2 4738/4885CA7 3940/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | CA1 3620/4885CA2 2717/4885CA7 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.